Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:52:35.036Z.
Calculation as of: 2026-10-06T14:52:35.036Z.
Quote observation: 2026-10-06T14:50:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a840c676881d241076febf00b391d6b63dc7604cd07ac1d060a0848db02ea459
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Inhibikase Therapeutics, Inc.
Market Cap
$260.03M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$260.47M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.42M
EV/EBITDA Ratio
N/A
TTM Avg
10.21x
3Y Avg
10.21x
5Y Avg
10.68x
Market Cap
$256.28M
EV/EBITDA Ratio
473.84x
TTM Avg
197.45x
3Y Avg
157.93x
5Y Avg
101.85x
Market Cap
$255.24M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$252.78M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$272.91M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $260.03M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $260.47M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $262.58M | N/A | 15.20x | 12.43x | 15.17x |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.42M | N/A | 10.21x | 10.21x | 10.68x |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.28M | 473.84x | 197.45x | 157.93x | 101.85x |
| Century Therapeutics, Inc. (IPSC)vs › | $255.24M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $252.78M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $272.65M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $276.57M | N/A | 10.42x | 23.40x | 23.40x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
